In a recent article published in Nature Cancer, a multi-institutional research team led by The University of Osaka describes ...

在haplo-HCT后第+1天和第+4天预防性使用巴利昔单抗安全性良好，可显著降低CR-AML患者II-IV级aGVHD的发生率，而不会影响长期预后。其疗效在不同AML亚型间存在差异，其中M1和M4亚型患者获益最显著，而M7亚型的疗效最差。这些结果表 ...

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified ...

Akriti Jain, MD, discussed how emerging data on non-ABL1 mutations is reshaping chronic myeloid leukemia management.

The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the ...

Scientists have identified a promising new drug target for acute myeloid leukemia, a deadly blood cancer with a five-year ...

Moleculin Biotech has begun dosing subjects in a Phase III trial of Annamycin with Cytarabine for treating acute myeloid ...

The following is a summary of “Efficacy and safety of decitabine combined with arsenic trioxide in elderly high-risk ...

"It's way more important than anything I do on the field. I love what I do on the field, but, I mean, this is what it's ...

研究结论和讨论部分指出，生成对抗网络（GANs）能够生成高质量的 BMS ...

Monzr M. Al Malki, MD, discussed data for AlloHeme, a blood test used to detect risk of relapse post-transplant in patients ...